Search: onr:"swepub:oai:prod.swepub.kib.ki.se:138643829" >
A selective high af...
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation
-
Castell, A (author)
-
Yan, QZ (author)
-
Fawkner, K (author)
-
show more...
-
- Hydbring, P (author)
- Karolinska Institutet
-
- Zhang, F (author)
- Karolinska Institutet
-
Verschut, V (author)
-
- Franco, M (author)
- Karolinska Institutet
-
- Zakaria, SM (author)
- Karolinska Institutet
-
- Bazzar, W (author)
- Karolinska Institutet
-
Goodwin, J (author)
-
- Zinzalla, G (author)
- Karolinska Institutet
-
- Larsson, LG (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2018-07-03
- 2018
- English.
-
In: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 8:1, s. 10064-
- Related links:
-
https://www.nature.c...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- MYC is a key player in tumor development, but unfortunately no specific MYC-targeting drugs are clinically available. MYC is strictly dependent on heterodimerization with MAX for transcription activation. Aiming at targeting this interaction, we identified MYCMI-6 in a cell-based protein interaction screen for small inhibitory molecules. MYCMI-6 exhibits strong selective inhibition of MYC:MAX interaction in cells and in vitro at single-digit micromolar concentrations, as validated by split Gaussia luciferase, in situ proximity ligation, microscale thermophoresis and surface plasmon resonance (SPR) assays. Further, MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a KD of 1.6 ± 0.5 μM as demonstrated by SPR. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner with IC50 concentrations as low as 0.5 μM, while sparing normal cells. The response to MYCMI-6 correlates with MYC expression based on data from 60 human tumor cell lines and is abrogated by MYC depletion. Further, it inhibits MYC:MAX interaction, reduces proliferation and induces massive apoptosis in tumor tissue from a MYC-driven xenograft tumor model without severe side effects. Since MYCMI-6 does not affect MYC expression, it is a unique molecular tool to specifically target MYC:MAX pharmacologically and it has good potential for drug development.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Castell, A
-
Yan, QZ
-
Fawkner, K
-
Hydbring, P
-
Zhang, F
-
Verschut, V
-
show more...
-
Franco, M
-
Zakaria, SM
-
Bazzar, W
-
Goodwin, J
-
Zinzalla, G
-
Larsson, LG
-
show less...
- Articles in the publication
-
Scientific repor ...
- By the university
-
Karolinska Institutet